Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a chronic progressive disease, defined by insulin resistance and insufficient insulin secretion to maintain normoglycemia. Amyloidogenic aggregates are a hallmark of T2DM patients; they are cytotoxic for the insulin producing β-cells, and cause inflammasome-depende...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne-Cathrine S. Vogt, Elisa S. Roesti, Mona O. Mohsen, Ainars Leonchiks, Monique Vogel, Martin F. Bachmann
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	islet amyloid polypeptide (IAPP) amyloid type 2 diabetes (T2DM) monoclonal antibody (mAb) amylin Medicine R
Acceso en línea:	https://doaj.org/article/e74c474167774d908f767972862a48e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e74c474167774d908f767972862a48e8
record_format	dspace
spelling	oai:doaj.org-article:e74c474167774d908f767972862a48e82021-11-25T19:11:16ZAnti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes10.3390/vaccines91113162076-393Xhttps://doaj.org/article/e74c474167774d908f767972862a48e82021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1316https://doaj.org/toc/2076-393XType 2 Diabetes Mellitus (T2DM) is a chronic progressive disease, defined by insulin resistance and insufficient insulin secretion to maintain normoglycemia. Amyloidogenic aggregates are a hallmark of T2DM patients; they are cytotoxic for the insulin producing β-cells, and cause inflammasome-dependent secretion of IL-1β. To avoid the associated β-cell loss and inflammation in advanced stage T2DM, we developed a novel monoclonal therapy targeting the major component of aggregates, islet amyloid polypeptide (IAPP). The here described monoclonal antibody (mAb) m81, specific for oligomeric and fibrils, but not for soluble free IAPP, is able to prevent oligomer growth and aggregate formation in vitro, and blocks islet inflammation and disease progression in vivo. Collectively, our data show that blocking fibril formation and prevention of new amyloidogenic aggregates by monoclonal antibody therapy may be a potential therapy for T2DM.Anne-Cathrine S. VogtElisa S. RoestiMona O. MohsenAinars LeonchiksMonique VogelMartin F. BachmannMDPI AGarticleislet amyloid polypeptide (IAPP)amyloidtype 2 diabetes (T2DM)monoclonal antibody (mAb)amylinMedicineRENVaccines, Vol 9, Iss 1316, p 1316 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	islet amyloid polypeptide (IAPP) amyloid type 2 diabetes (T2DM) monoclonal antibody (mAb) amylin Medicine R
spellingShingle	islet amyloid polypeptide (IAPP) amyloid type 2 diabetes (T2DM) monoclonal antibody (mAb) amylin Medicine R Anne-Cathrine S. Vogt Elisa S. Roesti Mona O. Mohsen Ainars Leonchiks Monique Vogel Martin F. Bachmann Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
description	Type 2 Diabetes Mellitus (T2DM) is a chronic progressive disease, defined by insulin resistance and insufficient insulin secretion to maintain normoglycemia. Amyloidogenic aggregates are a hallmark of T2DM patients; they are cytotoxic for the insulin producing β-cells, and cause inflammasome-dependent secretion of IL-1β. To avoid the associated β-cell loss and inflammation in advanced stage T2DM, we developed a novel monoclonal therapy targeting the major component of aggregates, islet amyloid polypeptide (IAPP). The here described monoclonal antibody (mAb) m81, specific for oligomeric and fibrils, but not for soluble free IAPP, is able to prevent oligomer growth and aggregate formation in vitro, and blocks islet inflammation and disease progression in vivo. Collectively, our data show that blocking fibril formation and prevention of new amyloidogenic aggregates by monoclonal antibody therapy may be a potential therapy for T2DM.
format	article
author	Anne-Cathrine S. Vogt Elisa S. Roesti Mona O. Mohsen Ainars Leonchiks Monique Vogel Martin F. Bachmann
author_facet	Anne-Cathrine S. Vogt Elisa S. Roesti Mona O. Mohsen Ainars Leonchiks Monique Vogel Martin F. Bachmann
author_sort	Anne-Cathrine S. Vogt
title	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
title_short	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
title_full	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
title_fullStr	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
title_full_unstemmed	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
title_sort	anti-iapp monoclonal antibody improves clinical symptoms in a mouse model of type 2 diabetes
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e74c474167774d908f767972862a48e8
work_keys_str_mv	AT annecathrinesvogt antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes AT elisasroesti antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes AT monaomohsen antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes AT ainarsleonchiks antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes AT moniquevogel antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes AT martinfbachmann antiiappmonoclonalantibodyimprovesclinicalsymptomsinamousemodeloftype2diabetes
_version_	1718410251608260608

Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes

Ejemplares similares